BACKGROUND: Many cancer patients suffer from cancer-related fatigue (CRF) both during and after their treatment. CRF can arise at any point in the course of the disease and can be either self-limited or persistent, sometimes for years. It gives rise to a vicious circle of impaired physical performance, avoidance of exertion, inactivity, inadequate physical recovery, helplessness, and depressed mood. Its hallmarks are tiredness, exhaustion, and lack of energy; it can impair performance so severely that the patient is unable to work. It is associated with increased mortality. Cancer patients are hardly ever systematically asked about the symptoms and signs of CRF. The stress and impairments that it produces are often inadequately appreciated, and the opportunities for treatment often neglected. METHOD: Selective review of the pertinent literature, including published guidelines from Germany and abroad. RESULTS: The pathogenesis of CRF is complex, involving an interaction of somatic, emotional, cognitive, and psychosocial factors, with a highly variable pattern of clinical expression. Clinical history-taking plays a key role in diagnostic assessment. Depressive disorders must be considered in the differential diagnosis. Many randomized trials and meta-analyses have documented the efficacy of pharmacological and non-pharmacological treatments for CRF. CONCLUSION: Cancer-related fatigue is a serious problem that impairs patients physically, mentally, and socially. Physicians need to know how to recognize and treat it.
BACKGROUND: Many cancerpatients suffer from cancer-related fatigue (CRF) both during and after their treatment. CRF can arise at any point in the course of the disease and can be either self-limited or persistent, sometimes for years. It gives rise to a vicious circle of impaired physical performance, avoidance of exertion, inactivity, inadequate physical recovery, helplessness, and depressed mood. Its hallmarks are tiredness, exhaustion, and lack of energy; it can impair performance so severely that the patient is unable to work. It is associated with increased mortality. Cancerpatients are hardly ever systematically asked about the symptoms and signs of CRF. The stress and impairments that it produces are often inadequately appreciated, and the opportunities for treatment often neglected. METHOD: Selective review of the pertinent literature, including published guidelines from Germany and abroad. RESULTS: The pathogenesis of CRF is complex, involving an interaction of somatic, emotional, cognitive, and psychosocial factors, with a highly variable pattern of clinical expression. Clinical history-taking plays a key role in diagnostic assessment. Depressive disorders must be considered in the differential diagnosis. Many randomized trials and meta-analyses have documented the efficacy of pharmacological and non-pharmacological treatments for CRF. CONCLUSION:Cancer-related fatigue is a serious problem that impairs patients physically, mentally, and socially. Physicians need to know how to recognize and treat it.
Authors: N J Vogelzang; W Breitbart; D Cella; G A Curt; J E Groopman; S J Horning; L M Itri; D H Johnson; S L Scherr; R K Portenoy Journal: Semin Hematol Date: 1997-07 Impact factor: 3.851
Authors: Fernando C Dimeo; Frank Thomas; Cornelia Raabe-Menssen; Felix Pröpper; Michael Mathias Journal: Support Care Cancer Date: 2004-11 Impact factor: 3.603
Authors: K Lundholm; J Gelin; A Hyltander; C Lönnroth; R Sandström; G Svaninger; U Körner; M Gülich; I Kärrefors; B Norli Journal: Cancer Res Date: 1994-11-01 Impact factor: 12.701
Authors: Andrea M Barsevick; William Dudley; Susan Beck; Carole Sweeney; Kyra Whitmer; Lillian Nail Journal: Cancer Date: 2004-03-15 Impact factor: 6.860
Authors: Francisco Álvarez-Salvago; Noelia Galiano-Castillo; Manuel Arroyo-Morales; Mayra Cruz-Fernández; Mario Lozano-Lozano; Irene Cantarero-Villanueva Journal: Support Care Cancer Date: 2018-05-05 Impact factor: 3.603
Authors: Simone Oerlemans; Floortje Mols; Djamila E Issa; J H F M Pruijt; Wim G Peters; Marnix Lybeert; Wobbe Zijlstra; Jan Willem W Coebergh; Lonneke V van de Poll-Franse Journal: Haematologica Date: 2012-08-28 Impact factor: 9.941